EPICS Therapeutics to Acquire Ogeda former assets, Adding Drug Discovery & Development Capabilities

Press release03.01.19

News

Brussels, Belgium, Dec 21st, 2018 

EPICS Therapeutics SA, a recently launched biotech company (April 2018) focused on discovery and development of innovative small molecules anti-cancer drugs acting on RNA epigenetics, today announced it has entered into a Business Transfer Agreement with Ogeda SA. On Dec 31st 2018, part of the Ogeda assets, including research stage programs and the EuroscreenFast Business Services Unit will be acquired by EPICS.  The financial details of the transaction are not disclosed. In parallel of this acquisition, EPICS will also raise €14.2 Million ($16.1 Million) to fund further developments. All current shareholders of EPICS, including Newton BioCapital and SRIW will participate to this new round, and will be joined by new comers including Fund+, SFPI-FPIM, and BNP Paris Fortis Private Equity. Jean Combalbert, PharmD, PhD, who was the former CEO of Ogeda before Astellas Pharma Inc. acquisition, and now CEO of EPICS mentioned, “With this acquisition, EPICS will take a big step forward that will allow us to accelerate our development over the next years, creating a world leading epidrugs’ company with capabilities and resources with successful track-record, including highly qualified staff”.
 
_________________________________
 

Contacts

Jean Combalbert, PharmD, PhD
CEO
jcombalbert@epicstx.com (from Jan 1st 2019)
+32 485 339 876

François Fuks, PhD
CSO
ffuks@epicstx.com (from Jan 1st 2019)
+32 485 382 313

 

About EPICS Therapeutics

EPICS Therapeutics is a Belgian drug discovery and development company. EPICS develops innovative small molecules acting through novel RNA epigenetic targets for cancer treatment. Recent discovery efforts targeting DNA and histone modifications have already given some of the most promising drugs to treat cancer. Modifications to RNA are much more common than to DNA, further highlighting the huge potential of using RNA epigenetics for therapeutic applications. By targeting RNA modifications, EPICS aims to translate science into life-changing therapies for patients. www.epicstherapeutics.com